News|Podcasts|January 9, 2024
Prioritizing R&D Initiatives to Support Cell Line Development
Author(s)AGC Biologics
Robust, scalable manufacturing of novel therapeutics requires partnering with a CDMO equipped to adapt to changes in the market and knowledgeable on the latest technologies used to support cell line development.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Novartis Calls for Global Governments to Address Global Trade Policy
2
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Beyond Transactional: Collaborative Partnerships for Rapid, Flexible Biologics Development
5